EphB4 Forward-Signaling Regulates Cardiac Progenitor Development in Mouse ES Cells

Kang Chen, Hao Bai, Yanfeng Liu, Dixie L. Hoyle, Wei-Feng Shen, and Zack Z. Wang

Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

ABSTRACT

Eph receptor (Eph)-ephrin signaling plays an important role in organ development and tissue regeneration. Bidirectional signaling of EphB4–ephrinB2 regulates cardiovascular development. To assess the role of EphB4–ephrinB2 signaling in cardiac lineage development, we utilized two GFP reporter systems in embryonic stem (ES) cells, in which the GFP transgenes were expressed in Nkx2.5⁺ cardiac progenitor cells and in α-MHC⁺ cardiomyocytes, respectively. We found that both EphB4 and ephrinB2 were expressed in Nkx2.5-GFP⁺ cardiac progenitor cells, but not in α-MHC-GFP⁺ cardiomyocytes during cardiac lineage differentiation of ES cells. An antagonist of EphB4, TNYL-RAW peptides, that block the binding of EphB4 and ephrinB2, impaired cardiac lineage development in ES cells. Inhibition of EphB4–ephrinB2 signaling at different time points during ES cell differentiation demonstrated that the interaction of EphB4 and ephrinB2 was required for the early stage of cardiac lineage development. Forced expression of human full-length EphB4 or intracellular domain-truncated EphB4 in EphB4-null ES cells was established to investigate the role of EphB4-forward signaling in ES cells. Interestingly, while full-length EphB4 was able to restore the cardiac lineage development in EphB4-null ES cells, the truncated EphB4 that lacks the intracellular domain of tyrosine kinase and PDZ motif failed to rescue the defect of cardiomyocyte development, suggesting that EphB4 intracellular domain is essential for the development of cardiomyocytes. Our study provides evidence that receptor-kinase-dependent EphB4-forward signaling plays a crucial role in the development of cardiac progenitor cells. J. Cell. Biochem. 116: 467–475, 2015.

KEY WORDS: EMBRYONIC STEM (ES) CELLS; CARDIOMYOCYTES; EphB4; ephrinB2; CARDIAC PROGENITOR CELLS; Nkx 2.5; α-MHC

Understanding the molecular and cellular mechanisms underlying stem cell differentiation into cardiomyocytes will provide insights into therapeutic applications for prevention and treatment of heart failure. A strong contender involved in stem cell differentiation is Eph-ephrin signaling. Fourteen Eph receptor tyrosine kinases are catalogued into EphA and EphB subclasses based on their affinity for ephrin ligands that are either glycosylphosphatidylinositol (GPI)-linked (ephrinA) or transmembrane (ephrinB) proteins [Committee, 1997]. Eph-ephrin signaling plays important roles in a variety of processes during embryonic development, including the targeting behavior of migratory neurons, vascular cell assembly, and angiogenesis.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Kang Chen and Hao Bai equally contribute to this work.
Conflicts of interest: The authors declare no conflicts of interest.
Author Contributions: K.C.: collection and assembly of data, manuscript writing; H.B.: collection and assembly of data; Y.L. and D.H.: collection of data; W.F.S.: data analysis and interpretation, contribution of vital new reagents; L.Q.W. and Z.Z.W.: conception and design, data analysis and interpretation, and manuscript writing.
Grant sponsor: MD State Stem Research Cell Fund; Grant numbers: 2012-MSRCRFII-0124, NIH/NHLBI U01 HL107446; Grant sponsor: National Natural Science Foundation of China; Grant numbers: 30900604, 81270004; Grant sponsor: New Outstanding Youth Program of Shanghai Municipal Commission of Health and Family Planning; Grant number: XYQ2013105.
*Correspondence to: Li-qun Wu, Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. E-mail: wuliqun89@hotmail.com
**Correspondence to: Zack Z. Wang, Division of Hematology, Johns Hopkins University School of Medicine, 720 Rutland Ave, Ross 1029, Baltimore, MD 21205. E-mail: zwang51@jhmi.edu
Manuscript Received: 22 August 2014; Manuscript Accepted: 20 October 2014
Accepted manuscript online in Wiley Online Library (wileyonlinelibrary.com): 30 October 2015
DOI 10.1002/jcb.25000 © 2014 The Authors. Journal of Cellular Biochemistry published by Wiley Periodicals, Inc.
[Gale and Yancopoulos, 1999; Poliakov et al., 2004; Egea and Klein, 2007; Arvanitis and Davy, 2008; Pasquale, 2008]. Rather than long range communication, Eph receptors and their ligands signal at restricted sites of direct cell–cell contact, resulting in reciprocal bidirectional events between interacting cells [Davis et al., 1994; Bruckner and Klein, 1998; Gale and Yancopoulos, 1999; Poliakov et al., 2004; Egea and Klein, 2007; Arvanitis and Davy, 2008; Pasquale, 2008]. When EphB4 receptor interacts with ephrinB2 ligand, the EphB4-forward signaling exerts in a receptor-kinase-dependent manner, and ephrinB2-reverse signaling is independent of the tyrosine kinase of EphB4 receptor [Fuller et al., 2003; Chrencik et al., 2006].

The potential importance of EphB4–ephrinB2 signaling in cardiovascular development has been demonstrated by loss-of-function approaches [Wang et al., 1998; Adams et al., 1999; Gerety et al., 1999; Gerety and Anderson, 2002; Cowan et al., 2004]. During embryonic development, EphB4 and ephrinB2 are expressed in the vascular endothelium and in the heart ventricles [Wang et al., 1998; Adams et al., 1999; Gerety et al., 1999; Gerety and Anderson, 2002; Cowan et al., 2004]. Global knockout of EphB4 or ephrinB2 in mice results in not only defective vascular development, but also arrested heart development, including decrease of heart size, incompleteness of cardiac looping, failure of endocardium expansion, failure of myocardial trabeculation, and thickened cardiac valves [Wang et al., 1998; Adams et al., 1999; Gerety et al., 1999; Gerety and Anderson, 2002; Cowan et al., 2004]. Knockout of EphB4 and the cognate ligand ephrinB2 is embryonic lethal in mice and therefore its role in cardiac lineage development remains poorly defined.

Pluripotent stem cells, such as embryonic stem (ES) cells and induced pluripotent stem (iPS) cells, provide an excellent model system for investigation of molecular and cellular mechanisms of cardiac development and cardiac diseases [Chen et al., 2008]. Our previous studies of ES cells demonstrated that endothelial cells provide a stem cell niche to promote ES cell differentiation into cardiomyocytes, and that EphB4 signaling regulates endothelial niche function [Chen et al., 2010]. In the current study, we found that EphB4 and ephrinB2 were expressed in Nkx2.5+ cardiac progenitor cells, but not in α-MHC+ cardiomyocytes during murine ES cell differentiation. Disrupting the interaction of EphB4 and ephrinB2 at the early stage of ES cell differentiation impaired cardiac lineage development. Reconstitution of EphB4 in EphB4-null ES cells demonstrated that EphB4 intracellular domain was essential for ES cell differentiation to cardiomyocytes. Our data indicates that EphB4-forward signaling is involved in cardiac progenitor development.

MATERIALS AND METHODS

CELL CULTURE

The α-MHC-GFP mouse ES cell line (CGR8-GFP) was generously provided by Dr. Richard T. Lee (Harvard Medical School, Boston, MA). The expression of enhanced GFP (EGFP) transgene is under the control of cardiac muscle specific α-MHC promoter (α-MHC) [Takahashi et al., 2003]. Nkx2.5-GFP mouse ES cell line (Nkx2.5-EmGFP) was generously provided by Dr. Edward Hsiao (Gladstone Institute of Cardiovascular Disease). The emerald GFP (EmGFP) reporter is knock-in at Nkx2.5 locus 26 amino acids downstream of the native ATG site in a human BAC vector [Hsiao et al., 2008].

Mouse ES cells were cultured as we previously described [Wang et al., 2004; Chen et al., 2010]. Briefly, ES cells were maintained on a mouse feeder cell line (SNL) in Dulbecco’s modified Eagle medium (DMEM) containing 10% fetal bovine serum (FBS; HyClone, Logan, UT), 2 mM sodium pyruvate, 2 mM L-glutamine, 0.1 M nonessential amino acid, 150 μM monothioglycerol (MTG; Sigma–Aldrich, St. Louis, MO), 50 U/ml penicillin, 50 μg/ml streptomycin, and 10 ng/ml leukemia inhibitory factor (LIF; Chemicon International). The ES cells were cultured on gelatin-coated plates for two passages to remove feeder cells before EB differentiation.

CARDIOMYOCYTE DIFFERENTIATION OF ES CELLS

ES cell differentiation into embryoid bodies (EBs) was performed as described previously [Chen et al., 2010]. Briefly, 400 ES cells were suspended in hanging-drop cultures in 30 μl differentiation medium containing Iscove modified Dulbecco’s medium (IMDM), 15% defined-FBS, 2 mM L-glutamine, 50 U/ml penicillin, and 50 μg/ml streptomycin. After 5 days of differentiation, individual EBs were transferred to a gelatin-coated well in 48-well plates. Differentiation medium was changed every 3 days. After 5 to 8 days of differentiation, GFP+ cardiomyocytes from α-MHC–GFP, and GFP+ cardiac progenitor cells from Nkx2.5-GFP ES cells were observed under a fluorescent microscope.

ES cell differentiation was carried out with or without TNYL-RAW (5 μM). The TNYL-RAW peptide (TNYLFSPNGPIARAW) is an antagonist of EphB4–phrinB2 binding to EphB4 [Koolpe et al., 2005]. The control peptide (WYPNSTRPGILNAFA) contains a scramble sequence of TNYL-RAW. Both the TNYL-RAW and control peptide were synthesized by EZBiolab (www.ezbiolab.com; Westfield, IN). TNYL-RAW, or a control peptide was added into the differentiation medium at different time points, depending on experiment design.

QUANTITATIVE PCR (Q-PCR) ANALYSIS

Undifferentiated ES cells and differentiated EBs were harvested at different time points. Total RNA was extracted with TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA). One microgram RNA was used to generate cDNA in 20 μl by reverse transcription (RT) using SuperScript III reverse transcriptase (Invitrogen). For quantitative PCR (real-time PCR), 0.5 μl of cDNA was added to 19.5 μl of master mix containing 1X SYBR Green (Bio–Rad Laboratories, Hercules, CA) and 25 mM sense and antisense primers. Triplicates of the cDNA were amplified for 40 cycles with the iCycler IQ real-time thermal cycler (Bio–Rad Laboratories). The PCR product level was expressed as Ct, the amplification cycle at which the emission intensity of the product rises above an arbitrary threshold level. Specific primers used for Q-PCR are as previously described [Chen et al., 2010].

FLOW CYTOMETRIC ANALYSIS

Differentiated EBs at different time points were trypsinized for 2 min, dissociated with gentle agitation and passed through a 30 μm pre-
separation filter (Miltenyi Biotec Inc., Auburn, CA) to produce a single cell suspension. Cells ($1 \times 10^6$) were then stained with primary antibodies as follows: EphB4 at 1:100 dilution (R&D Systems, Minneapolis, MN), ephrinB2 at 1:100 dilution (R&D Systems), and rat IgG2a (control antibodies) at 1:100 dilution. PE- or APC-conjugated secondary antibodies were used for flow cytometric analysis. Dead cells were gated out by a DNA dye (7-Amino-Actinomycin D, 7AAD staining). Isotype-matched control antibodies were used to determine the background staining. All antibodies were purchased from BD Biosciences (Franklin Lakes, NJ). The cells were analyzed on FACSCalibur (BD Biosciences) with CellQuest software. Data analysis was performed using CellQuest or FlowJo Software.

Cell sorting was performed using Fluorescence Activated Cell Sorting (FACS) on FACS Aria II (BD Biosciences).

**GENERATION OF KO-HB4 CELLS BY LENTIVIRAL TRANSDUCTION**

The human EphB4 gene was cloned into a lentiviral vector pLentiGFPtc, in which EphB4 expression was driven by a mini-CMV inducible promoter, and constitutive expression of fluorescence marker GFP was driven by an individual EF-1alpha promoter [Bai et al., 2012]. The lentiviral vector pLentiGFPtc–EphB4 was transfected into 293 T-cells, respectively for lentivirus preparation. The lentivirus was concentrated by PEG-8000 and applied to transduce the mouse ESCs, as previously described [Wang et al., 2007; Bai et al., 2012]. Using fluorescence microscopy, the GFP$^+$ mouse ES cell colonies were manually picked up. After five passages of selection, the mouse ES cells capable of induced expression of EphB4 (KO-hB4) were established.

**WESTERN BLOT ANALYSIS**

Expression of Ephb4 was monitored by Western blot analysis. To induce Ephb4 expression, doxycycline of various concentrations (0, 500, and 1,000 ng/ml) was added to the mouse ES cell growth medium for 2 days, and then the cells were lysed in RIPA buffer (1% Triton X-100, 0.1% SDS, 1% sodium deoxycholate, 1 mM EDTA, 1 mM sodium orthovanadate, 1 mM sodium fluoride, 10 μM leupeptin, 150 mM NaCl, 50 mM Tris, pH 7.4) supplemented with 1% protease inhibitor cocktail (Sigma–Aldrich) [Bai et al., 2012]. Western blot analyses were performed with anti-Ephb4 antibodies (BD Biosciences) as primary antibodies and anti-rabbit IgG–HRP antibodies (Sigma–Aldrich) as secondary antibodies. The protein expression levels were quantified using Photoshop software based on band area and gray scale.

**RESULTS**

**EXPRESSION OF EphB4 AND ephrinB2 IN NKK2.5$^+$ CARDIAC PROGENITOR CELLS, BUT NOT IN α- MHC$^+$ CARDIOMYOCYTES**

To investigate how EphB4 signaling regulates cardiomyocyte generation, we assessed Ephb4 and ephrinB2 expression during ES cell differentiation to cardiomyocytes. We induced ES cell differentiation by hanging-drop method to form uniformed EBs (Fig. 1A). After 5 days in hanging-drop, individual EBs were transferred to a gelatin-coated well in 48-well plates, in which attached EBs undergo cardiomyocyte development [Chen et al., 2010]. The GFP$^+$ cardiomyocytes from α-MHC-GFP mouse ES cells usually form cell clusters that generate spontaneously beating areas after 8 to 9 days of differentiation (Fig. 1B). The spontaneous beating EBs that contained cardiomyocytes were scored at different days.

Two ES cell lines were used in cardiomyocyte differentiation in our study: (i) Nkx2.5-GFP ES cells in which GFP expression is controlled by Nkx2.5 promoter that is activated in cardiac progenitors [Hsiao et al., 2008]; and (ii) α-MHC-GFP ES cells in which GFP expression is controlled by the α-cardiac MHC promoter to ensure exclusive expression in spontaneous contracting cardiomyocytes in beating EBs [Takahashi et al., 2003]. We determined the kinetics of GFP expression in Nkx2.5-GFP ES cells and in α-MHC-ES cells during ES cell differentiation under a fluorescent microscope at different time points. Photos represented a beating EB and non-beating at day 10.
8, whereas GFP expression in α-MHC-GFP ES cells reached the highest levels at day 13 (Fig. 2B). Flow cytometry indicated that approximately 20% of the differentiated cells in EBs were GFP-positive in Nkx2.5-GFP ES cells at day 8 (Fig. 2C), whereas approximately 40% of the differentiated cells in EBs were GFP-positive in α-MHC-GFP ES cells at day 13 (Fig. 2D). To evaluate gene expression profiles in cardiac progenitors and cardiomyocytes, we used FACS to sort GFP + cells from Nkx2.5-GFP ES cells at day 8 and GFP + cardiomyocytes from α-MHC-GFP ES cells at day 13, respectively. Real-time PCR analysis of sorted GFP + cells indicated that Flk1, the mesoderm progenitor marker (Fig. 3A), and Nkx2.5, cardiac progenitor marker (Fig. 3B) were expressed in high levels in Nkx2.5 + cardiac progenitors, compared to their expression in α-MHC + cardiomyocytes. Meanwhile, GATA4, a critical transcription factor for cardiac development, was expressed in both cardiac progenitors and cardiomyocytes (Fig. 3C). Interestingly, both EphB4 and ephrinB2 were expressed in Nkx2.5 + cardiac progenitors, but not in α-MHC + cardiomyocytes (Fig. 3D and E), suggesting a role of EphB4-ephrinB2 signaling in early rather than later stage of cardiac lineage development.

**BLOCKAGE OF THE INTERACTION OF EphB4 AND ephrinB2 IN AN EARLY STAGE OF ES DIFFERENTIATION INHIBITS CARDIOMYOCYTE GENERATION**

To examine whether the interaction of EphB4 and ephrinB2 contributes to cardiomyocyte generation from ES cells, we used TNYL-RAW peptide to block the interaction of EphB4 and ephrinB2 during α-MHC-GFP ES cell differentiation. As shown in Figure 4A and B, the frequency of beating EBs and the number of GFP + cardiomyocytes were significantly decreased in the presence of TNYL-RAW peptide during cardiomyocyte differentiation, suggesting that a binding of EphB4 and ephrinB2 is required for cardiomyocyte generation. To further analyze the effect of EphB4-ephrinB2 signaling on cardiomyocyte generation, TNYL-RAW peptide was added at different time points during ES cell differentiation. As we expected, the effective time of EphB4-ephrinB2 signaling was in an early developmental stage. The addition of TNYL-RAW at day 0 (EB0) or day 2 (EB2) during ES cell differentiation dramatically decreased the numbers of beating EBs, whereas the addition of TNYL-RAW at day 5 (EB5) or later had no effect on the development of beating EBs (Fig. 4C), suggesting an important role of EphB4-ephrinB2 interaction/signaling during the early phase of cardiac lineage development.
EphB4 FORWARD-SIGNALING IS CRUCIAL FOR CARDIOMYOCYTE GENERATION

We previously demonstrated that the differentiation of ES cells into cardiomyocytes is impaired in EphB4-null ES cells [Wang et al., 2004], and this defect of cardiomyocyte generation in the absence of EphB4 expression can be rescued by co-culture of normal endothelial cells [Chen et al., 2010]. One possible explanation to this observation is that endothelial cells provide EphB4-mediated function to facilitate cardiomyocyte differentiation in EphB4-null ES cells. To analyze the function of EphB4 in promoting cardiomyocyte generation, we established an EphB4-expressing reconstitution system by a lentiviral system [Lois et al., 2002] to ectopically express the full-length of human EphB4 gene (hB4) in EphB4-null ES cells (KO). The forced expression of human EphB4 in EphB4-null ES cells (KO-hB4) was confirmed by real-time PCR analysis (Fig. 5A), Western blotting (Fig. 5B) and flow cytometry (Fig. 5C). As shown in Figure 5D, forced expression of human EphB4 in EphB4-null ES cells (KO-hB4) fully restored EB beating activity, confirming a critical role of EphB4 in cardiomyocyte generation.

In a further test, we used the inducible lentiviral system to express full length human EphB4 gene or a truncated EphB4 gene that lacks the intracellular domain in EphB4-null ES cells (Fig. 6A and C). The peptides were added at day 0, and through the end of differentiation. The frequency of beating EBs (A) and GFP+ cells (B) were analyzed at day 12. (C) The addition of TNYL-RAW peptides was initialized at different time points during ES cell differentiation: day 0 (EB0), day 2 (EB2), day 5 (EB5), or day 9 (EB9). ES cell differentiation was compared in the presence of the control peptide as added starting at day 0. Data are representative from three independent experiments. Error bars represent standard deviation and * represents P < 0.05.

Fig. 3. Quantitative analysis of gene expression by real-time PCR. GFP+ cells at day-8 EBs from Nkx2.5-GFP ES cells (Nkx2.5+), and GFP+ cells at day-13 EBs from α-MHC-GFP ES cells (αMHC+) were sorted by FACS. Total RNA was extracted from sorted GFP+ cells with TRIzol reagent, and subject to real-time PCR analysis for the gene expression of Flk1 (A), Nkx2.5 (B), GATA4 (C), ephrinB2 (D), and EphB4 (E). Undifferentiated ES cells (ESC) were used as a control. GAPDH was used as a standard. Error bars represent standard deviation and * represents P < 0.05.

Fig. 4. Impairing cardiac differentiation by blocking the interaction of EphB4 and ephrinB2 with TNYL-RAW peptide. α-MHC-GFP ES cells were differentiated into beating EBs in the presence of TNYL-RAW peptide (TNYLFSPNPGPARRAW). The peptides were added at day 0, and through the end of differentiation. The frequency of beating EBs (A) and GFP+ cells (B) were analyzed at day 12. (C) The addition of TNYL-RAW peptides was initialized at different time points during ES cell differentiation: day 0 (EB0), day 2 (EB2), day 5 (EB5), or day 9 (EB9). ES cell differentiation was compared in the presence of the control peptide as added starting at day 0. Data are representative from three independent experiments. Error bars represent standard deviation and * represents P < 0.05.
generation (Fig. 6D), indicating that EphB4-forward signaling is required for cardiomyocyte generation in ES cells.

To gain more insight into the mechanism of EphB4 function, we tested whether EphB4-expressing ES cells are able to provide paracrine signal for neighboring cells, and thereby rescue the cardiac defect in EphB4-null ES cells. We mixed KO-hB4 ES cells and KO ES cells at different ratios, and then subjected the mixture to cardiomyocyte differentiation. When KO-hB4 cells and KO cells were mixed at 1:1 ratio, approximately 33% of the EBs contained a beating activity. When the ratio of KO-hB4 cells versus KO cells was reduced to 1:3, beating-EBs decreased to less than 1% (Fig. 5D). These data demonstrated that, at least in tested expression level, EphB4 expression in neighboring cells was insufficient to promote cardiomyocyte generation in EphB4-null ES cells.

**DISCUSSION**

It is well-known that the receptor-tyrosine kinase, EphB4, and its ligand, ephrinB2, play a crucial role in angiogenesis. During vascular development, EphB4 and ephrinB2 are specifically expressed in venous and arterial endothelial cells, respectively [Wang et al., 1998; Gale et al., 2001; Shin et al., 2001]. In addition to the vascular defects, phenotypes of arrested heart development, including decreased heart size, incompleteness of cardiac looping, failure of endocardium expansion, failure of myocardial trabeculation, and thickened cardiac valves, have been observed in EphB4 or ephrinB2 gene knockout mice [Wang et al., 1998; Adams et al., 1999; Gerety et al., 1999; Gerety and Anderson, 2002; Cowan et al., 2004]. We previously demonstrated that EphB4 knockout in ES cells results in the defect of cardiomyocyte generation [Wang et al., 2004]. However, EphB4 is expressed in endothelial cells underneath contracting cardiomyocytes, but not in mature cardiomyocytes [Chen et al., 2010]. In this study, we found that in the absence of EphB4, the generation of beating cardiomyocytes were significantly reduced in EphB4-null ES cells (Fig. 6D), consistent with our previous study [Chen et al., 2010]. However, neither EphB4 nor ephrinB2 was expressed in cardiomyocytes (α-MHC-GFP ES cells) (Fig. 3D and E), suggesting that EphB4 signaling is not involved in the later stage of cardiomyocyte generation. Although EphB4 is not
expressed in cardiomyocytes, the function of EphB4 in regulating embryonic cardiac development can be accomplished by endothelial cells underneath cardiomyocytes [Chen et al., 2010].

ES cell-derived cardiomyocytes express cardiac gene products in a developmentally controlled manner. In early myocardial development, mRNAs encoding GATA4 and Nkx2.5 transcription factors appear in EBs before mRNAs encoding atrial natriuretic factor (ANF), myosin light chain (MLC)-2v, α-myosin heavy chain (α-MHC), β-myosin heavy chain (β-MHC), Na⁺-Ca²⁺ exchanger, and phospholamban [Boheler et al., 2002]. Nkx2.5, the homeobox gene, is the known earliest marker of the cardiac lineage in vertebrate embryos. Nkx2.5 expression is first detected in mesodermal cells specified to form the heart at embryonic day 7.5 in the mouse, and its expression is maintained throughout the developing and adult heart [Lien et al., 1999]. Nkx2.5 expression has been used to identify cardiac progenitors in differentiated ES cells [Hidaka et al., 2003]. In contrast, α-MHC is among cardiac-specific genes detectable relatively late in the developing heart and is the specific marker for cardiomyocytes [Gulick et al., 1991; Morkin 2000; Boheler et al., 2002; Takahashi et al., 2003]. Therefore, Nkx2.5 and α-MHC were used as early and later markers of cardiac lineage in our study.

By analysis of sorted GFP⁺ cells, we found that EphB4 and ephrinB2 were expressed in Nkx2.5⁺ cardiac progenitor cells, but not in α-MHC⁺ cardiomyocytes (Fig. 3). Interestingly, Nkx2.5⁺ cells also highly expressed Flk1 (Fig. 3A), a marker to identify cardiac stem/progenitor cells in ES cells [Sitnicka et al., 2003; Larochelle et al., 2011]. To test whether EphB4–ephrinB2 signaling is involved in early stage of cardiac lineage development, we utilized the EphB4/ephrinB2 antagonist peptide that binds to the ephrin-binding pocket of EphB4 with a high affinity at nanomolar range [Chrencik et al., 2006; Noberini et al., 2011]. To test whether EphB4–ephrinB2 signaling is involved in early stage of cardiac lineage development, we utilized the EphB4/ephrinB2 antagonist peptide that binds to the ephrin-binding pocket of EphB4 with a high affinity at nanomolar range [Chrencik et al., 2006; Noberini et al., 2011]. To test whether EphB4–ephrinB2 signaling is involved in early stage of cardiac lineage development, we utilized the EphB4/ephrinB2 antagonist peptide that binds to the ephrin-binding pocket of EphB4 with a high affinity at nanomolar range [Chrencik et al., 2006; Noberini et al., 2011]. To test whether EphB4–ephrinB2 signaling is involved in early stage of cardiac lineage development, we utilized the EphB4/ephrinB2 antagonist peptide that binds to the ephrin-binding pocket of EphB4 with a high affinity at nanomolar range [Chrencik et al., 2006; Noberini et al., 2011]. To test whether EphB4–ephrinB2 signaling is involved in early stage of cardiac lineage development, we utilized the EphB4/ephrinB2 antagonist peptide that binds to the ephrin-binding pocket of EphB4 with a high affinity at nanomolar range [Chrencik et al., 2006; Noberini et al., 2011].

Over the past decade, essential roles for Eph receptor-tyrosine kinases and their ligands, the ephrins, emerged from studies of embryonic development [Frisen et al., 1999]. EphB4–ephrinB2 interaction elicits bidirectional signaling events upon cell–cell
contact [Frisen et al., 1999; Kullander and Klein, 2002]. Bidirectional signaling of EphB4 and ephrinB2 is propagated not only downstream of EphB4 (forward-signaling) but also downstream of ephrinB2 (reverse-signaling). The EphB4-forward signaling exerts in a receptor-kinase-dependent manner, and ephrinB2-reverse signaling is through an EphB4-receptor-kinase-independent mechanism. It has been reported that between 8.0 and 9.5 days post coitum (dpc) of mouse embryos, EphB4 is expressed in myocardial cells, but not in endocardial cells. After 9.5 dpc, EphB4 expression is decreased, suggesting a role of EphB4 in development of the primitive heart [Ruiz et al., 1994]. Our data demonstrated for the first time that EphB4 and ephrinB2 are expressed in cardiac progenitors. Interestingly, ectopic expression of full-length EphB4 is sufficient to restore beating-EB development in EphB4-null ES cells, whereas truncated EphB4 failed to rescue the defect of cardiomyocyte differentiation (Fig. 6), suggesting that EphB4 kinase and downstream signaling were critical for cardiomyocyte development. However, considering our previous observation that co-culture of endothelial cells are able to rescue the defect of cardiomyocyte differentiation of EphB4-null ES cells [Chen et al., 2010], the role of EphB4 kinase and downstream signaling in cardiomyocyte differentiation may be carried out in an indirect mechanism. Further experiments are required to reveal the complex network of EphB4–ephrinB2 signaling in cardiomyocyte differentiation related events.

ACKNOWLEDGMENTS

This work was partially supported by MD State Stem Research Cell Fund (2012 MSCR01 0124) and NIH/NHLBI U01 HL107446. Project was also supported by the National Natural Science Foundation of China (Nos. 30900604 and 81270004), the New Outstanding Young Program of Shanghai Municipal Commission of Health and Family Planning (No. XYQ2013105), China.

REFERENCES

Adams RH, Wilkinson GA, Weiss C, Diella F, Gale NW, Deutsch U, Risau W, Klein R. 1999. Roles of ephrinB ligands and EphB receptors in cardiovascular development: Demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev 13(3):295–306.

Arvanitis D, Davy A. 2008. Eph/ephrin signaling: Networks. Genes Dev 22(4):416–429.

Bai H, Chen K, Gao Y, Arzigian M, Xie Y, Malcosky C, Yang Y, Wu W, Wang Z. 2012. Bel-xL enhances single-cell survival and expansion of human embryonic stem cells without affecting self-renewal. Stem Cell Res 8(1):26–37.

Boheler KR, Czyz J, Tweedie D, Yang HT, Anisimov SV, Wobus AM. 2002. Differentiation of pluripotent embryonic stem cells into cardiomyocytes. Circ Res 91(3):189–201.

Bruckner K, Klein R. 1998. Signaling by Eph receptors and their ephrin ligands. Curr Opin Neurobiol 8(3):375–382.

Chen K, Bai H, Arzigian M, Gao YY, Bao J, Wu WS, Shen WF, Wu L, Wang ZZ. 2010. Endothelial cells regulate cardiomyocyte development from embryonic stem cells. J Cell Biochem 111(1):29–39.

Chen K, Wu L, Wang ZZ. 2008. Extrinsic regulation of cardiomyocyte differentiation of embryonic stem cells. J Cell Biochem 104(1):119–128.

Chrencik JE, Broun A, Recht MI, Kraus ML, Koolpe M, Kolatkar AR, Bruce RH, Martiny-Baron G, Widmer H, Pasquale EB, Kuhn P. 2006. Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity. Structure 14(2):321–330.

Committee E. 1997. Unified nomenclature for Eph family receptors and their ligands, the ephrin. Cell 90(3):403–404.

Cowan CA, Yokoyama N, Saxena A, Chumley MJ, Silvany RE, Baker LA, Srivastava D, Henkemeyer M. 2004. Ephrin-B2 reverse signaling is required for axon pathfinding and cardiac valve formation but not early vascular development. Dev Biol 271(2):263–271.

Davis S, Gale NW, Aldrich TH, Maisonneuve PC, Lhotak V, Pawson T, Goldfarb M, Yancopolous GD. 1994. Ligands for Eph-related receptor tyrosine kinases that require membrane attachment or clustering for activity. Science 266(5186):816–819.

Egea J, Klein R. 2007. Bidirectional Eph-ephrin signaling during axon guidance. Trends Cell Biol 17(5):230–238.

Frisen J, Holmberg J, Barbacid M. 1999. Ephrins and their Eph receptors: Multitalented directors of embryonic development. Embryo J 18(19):5159–5165.

Fuller T, Korff T, Kilian A, Dandekar G, Augustin HG. 2003. Forward EphB4 signaling in endothelial cells controls cellular repulsion and segregation from ephrinB2 positive cells. J Cell Sci 116(Pt 12):2461–2470.

Gale NW, Baluk P, Pan L, Kwan M, Holash J, DeChiara TM, McDonald DM, Yancopolous GD. 2001. Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells. Dev Biol 230(2):151–160.

Gale NW, Yancopolous GD. 1999. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development, Genes Dev 13(9):1055–1066.

Gerety SS, Anderson DJ. 2002. Cardiovascular ephrinB2 function is essential for embryonic angiogenesis. Development 129(6):1397–1410.

Gerety SS, Wang HU, Chen ZF, Anderson DJ. 2002. Symmetrical mutant phenotypes of the receptor EphB4 and its speciﬁc transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell 4(3):403–414.

Gullick J, Subramaniam A, Neumann J, Robbins J. 1991. Isolation and characterization of the mouse cardiac myosin heavy chain genes. J Biol Chem 266(14):8180–8190.

Hidaka K, Lee JK, Kim HS, Ihm CH, Iio A, Ogawa M, Nishikawa S, Kodama I, Morisaki T. 2003. Chamber-specific differentiation of Nkx2.5-positive cardiac precursor cells from murine embryonic stem cells. FASEB J 17(6):740–742.

Hsiao EC, Yoshinaga Y, Nguyen TD, Musone SL, Kim JE, Swinton P, Espineda I, Malanac C, deJong PJ, Conklin BR. 2008. Marking embryonic stem cells with a 2 A self-cleaving peptide: A NKX2.5 emerald GFP BAC reporter. PLoS One 3(2):e2532.

Koolpe M, Burgess R, Dail M, Pasquale EB. 2005. EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity. J Biol Chem 280(17):17301–17311.

Kullander K, Klein R. 2002. Mechanisms and functions of Eph and ephrin signaling. Nat Rev Mol Cell Biol 3(7):475–486.

Larochelle A, Savona M, Wiggins M, Anderson S, Ichwan B, Keyvanfar K, Morrison SJ, Dunbar CE. 2011. Human and rhesus macaque hematopoietic stem cells cannot be purified based only on SLAM family markers. Blood 117(5):1550–1554.

Lien CL, Wu C, Mercer B, Webb R, Richardson JA, Olson EN. 1999. Control of early cardiac-specific transcription of Nkx2.5 by a GATA-dependent enhancer. Development 126(1):75–84.

Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D. 2002. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 295(5566):868–872.

Morkin E. 2000. Control of cardiac myosin heavy chain gene expression. Microse Res Tech 50(6):522–531.
Noberini R, Mitra S, Salvucci O, Valencia F, Duggineni S, Frigozhina N, Wei K, Tosato G, Huang Z, Pasquale EB. 2011. PEGylation potentiates the effectiveness of an antagonistic peptide that targets the EphB4 receptor with nanomolar affinity. PLoS One 6(12):e28611.

Pasquale EB. 2008. Eph-ephrin bidirectional signaling in physiology and disease. Cell 133(1):38–52.

Poliakov A, Cotrina M, Wilkinson DG. 2004. Diverse roles of eph receptors and ephrins in the regulation of cell migration and tissue assembly. Dev Cell 7(4):465–480.

Ruiz JC, Conlon FL, Robertson EJ. 1994. Identification of novel protein kinases expressed in the myocardium of the developing mouse heart. Mech Dev 48(3):153–164.

Salvucci O, de la Luz Sierra M, Martina JA, McCormick PJ, Tosato G. 2006. EphB2 and EphB4 receptors forward signaling promotes SDF-1-induced endothelial cell chemotaxis and branching remodeling. Blood 108(9):2914–2922.

Shin D, Garcia-Cardena G, Hayashi S, Gerety S, Asahara T, Stavrakis G, Isner J, Folkman J, Gimbrone MA Jr, Anderson DJ. 2001. Expression of ephrinB2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, and marks subsets of microvessels at sites of adult neovascularization. Dev Biol 230(2):139–150.

Sitnicka E, Buza-Vidas N, Larsson S, Nygren JM, Liuba K, Jacobsen SE. 2003. Human CD34+ hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express flt3: Distinct flt3 and c-kit expression and response patterns on mouse and candidate human hematopoietic stem cells. Blood 102(3):881–886.

Takahashi T, Lord B, Schulze PC, Fryer RM, Sarang SS, Gullans SR, Lee RT. 2003. Ascorbic acid enhances differentiation of embryonic stem cells into cardiac myocytes. Circulation 107(14):1912–1916.

Wang HU, Chen ZF, Anderson DJ. 1998. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93(5):741–753.

Wang Z, Cohen k, Shao Y, Mole P, Dombkowski D, Scadden T. 2004. Ephrin receptor, EphB4, regulates ES cell differentiation of primitive mammalian hemangioblasts, blood, cardiomyocytes, and blood vessels. Blood 103(1):100–109.

Wang ZZ, Au P, Chen T, Shao Y, Daheron LM, Bai H, Arzigian M, Fukumura D, Jain RK, Scadden DT. 2007. Endothelial cells derived from human embryonic stem cells form durable blood vessels in vivo. Nat Biotechnol 25(3):317–318.

Xiong C, Huang M, Zhang R, Song S, Lu W, Flores 2nd L, Gelovani J, Li C. 2011. In vivo small-animal PET/CT of EphB4 receptors using 64Cu-labeled peptide. J Nucl Med 52(2):241–248.

Zhang R, Xiong C, Huang M, Zhou M, Huang Q, Wen X, Liang D, Li C. 2011. Peptide-conjugated polymeric micellar nanoparticles for Dual SPECT and optical imaging of EphB4 receptors in prostate cancer xenografts. Biomaterials 32(25):5872–5879.